Stay in touch
We'd love to keep in touch about news, events and how you can get involved. To hear from us, please sign up below.
We answer some common questions about the current COVID-19 vaccines and breast cancer treatments.
Introduced in 2010 by the coalition government as a short-term measure while pricing of medicines was reformed, the Cancer Drugs Fund has so far been extended and had more money pumped into it to cope with increasing demand. The fund was originally worth £200 million per year and was due to expire in March 2014. It is now guaranteed until March 2016 and is worth £280 million per year.
Last week Welsh Assembly Members debated funding for cancer treatments and the Welsh Government faced calls to create a Cancer Treatments Fund, similar to the Cancer Drugs Fund (CDF) available in England. The debate followed the presentation of a petition signed by almost 100,000 people calling for fairer access to cancer drugs.
Your breasts go through a lot of changes during and after pregnancy. Our updated booklet Breast changes during and after pregnancy details some of these changes and problems that may occur.
Vivian was diagnosed with breast cancer in 2012 after a routine screening. She’s looking forward to hitting the catwalk at the Glasgow fashion show.
Today, these drugs are used to treat some breast cancer patients who have developed bone metastasis but new research reported today (7 November 2014) in the press could help repurpose these drugs for the treatment of breast cancer before it has spread.
Today (6 November 2014) is an exciting day for Breakthrough’s Policy & Information team – it marks the launch in Parliament of an important piece of work we are doing on prevention with The Richmond Group of Charities, a coalition of 10 of the UK’s leading health and social care charities. Seeing as it’s only been a week since the parliamentary launch of our Demand a Fair Price campaign, it’s been a busy few weeks for the team!
The day began with a selection of talks about the likely future of important cancer topics. First up was Andrew Hughes from pharmaceutical giant AstraZeneca. He took a look back at the recent history of clinical trials and the testing of new treatments in patients and gave us some insight into what we can expect from these in the future.